1.19
-0.05(-4.03%)
Currency In USD
| Previous Close | 1.24 |
| Open | 1.22 |
| Day High | 1.24 |
| Day Low | 1.14 |
| 52-Week High | 6.8 |
| 52-Week Low | 0.8 |
| Volume | 216,614 |
| Average Volume | 445,122 |
| Market Cap | 64.12M |
| PE | -0.67 |
| EPS | -1.77 |
| Moving Average 50 Days | 1.21 |
| Moving Average 200 Days | 3.48 |
| Change | -0.05 |
If you invested $1000 in Prelude Therapeutics Incorporated (PRLD) since IPO date, it would be worth $45.42 as of December 26, 2024 at a share price of $1.19. Whereas If you bought $1000 worth of Prelude Therapeutics Incorporated (PRLD) shares 3 years ago, it would be worth $94.75 as of December 26, 2024 at a share price of $1.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
GlobeNewswire Inc.
Dec 11, 2024 12:30 PM GMT
• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy • Prelude plans to seek a partner for future development of PRT2527 in hematologic malignancies WILMINGTO
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
GlobeNewswire Inc.
Nov 27, 2024 12:30 PM GMT
WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 06, 2024 9:05 PM GMT
Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical proof of concept Initiated a Phase 1 trial for PRT7732, its first-in-class oral SMARCA2 degrader in patie